Incidence and prognostic factors for seroma development after MammoSite breast brachytherapy.
OBJECTIVE
Describe the incidence and identify risk factors for seroma development after MammoSite breast brachytherapy (MBT).


METHODS
MBT patient data were prospectively recorded into a quality assurance database. Departmental and electronic records were reviewed to extract patient-, treatment-, and outcome-specific data. Stepwise logistic regression analysis was performed to identify factors associated with development of any seroma including the subset of clinically significant seroma (CSS). CSS was defined as a symptomatic seroma requiring multiple aspirations, biopsy, and/or excision. Variables analyzed included age, weight, number of excisions, time from resection to catheter placement, placement technique, balloon volume, dosimetric factors, and postbrachytherapy infection.


RESULTS
MBT was performed in 109 patients, of whom 97 had minimum 6 months (median, 36) post-MBT follow-up or earlier development of seroma. All patients received 34 Gy to 1cm depth from balloon surface, delivered twice daily in 10 fractions. Seroma developed in 41% of patients at a median of 3 months (range, 0.1-25) post-MBT. One-third of seromas (13% of all patients) were CSS. The only factor identified as statistically significant for development of any seroma was catheter placement on day of resection vs. > or =1 day later (59% vs. 33%; p = 0.0066). Post-MBT infection was highly statistically significant for development of CSS (64% vs. 7%; p<0.0001). Prophylactic antibiotics reduced the risk of post-MBT infection from 37.5% to 6% (p = 0.011).


CONCLUSIONS
The incidence of CSS after MBT is low. Post-MBT infection is statistically significantly associated with CSS development, the incidence of which is reduced with prophylactic antibiotics.
Watkins
John M
JM
Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA.
Harper
Jennifer L
JL
Dragun
Anthony E
AE
Ashenafi
Michael S
MS
Sinha
Debajyoti
D
Li
Jun
J
Cole
David J
DJ
Jenrette
Joseph M
JM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects* / Q000295:instrumentation*; D001943:Breast Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000532:radiotherapy* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental / Q000009:adverse effects*; D008875:Middle Aged; D011446:Prospective Studies; D049291:Seroma / Q000209:etiology*; D013530:Surgical Wound Infection / Q000150:complications
Arch Surg. 1989 Feb;124(2):153-7
2916935
Jpn J Clin Oncol. 2006 Apr;36(4):197-206
16684859
Am J Surg. 2007 Oct;194(4):456-62
17826055
Am J Surg. 2006 Oct;192(4):427-33
16978943
Arch Surg. 2004 Jun;139(6):603-7; discussion 607-8
15197085
Wound Repair Regen. 2003 Sep-Oct;11(5):326-30
12950635
Radiother Oncol. 2006 Jun;79(3):316-20
16780977
Am Surg. 2006 Oct;72(10):929-34
17058738
J Clin Oncol. 1992 Mar;10(3):356-63
1445509
Am Surg. 2000 May;66(5):444-50; discussion 450-1
10824744
Am J Surg. 2005 Oct;190(4):530-8
16164915
Surg Clin North Am. 2007 Apr;87(2):431-51, x
17498536
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):333-9
16545918